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INTRODUCTION
Cervical cancer represents the second most common gyne-
cologic malignancy worldwide. Various molecular and epi-
demiologic studies have established a strong association bet-
ween high-risk (HR) human papillomavirus (HPV) geno-
types and the development of cervical cancer and its precur-
sor lesions, cervical intraepithelial neoplasia (CIN) 2 or 3 (1-
5). The majority of cases of cervical cancer is caused by infec-
tion with at least 1 of the 13 accepted HR carcinogenic HPV
types (i.e., types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, and 68) (1, 3, 5). Among the carcinogenic HPV types,
HPV 16 and HPV 18 account for approximately 70% of all
cervical cancers (6). Consequently, it has been proposed that
highly sensitive HPV detection methods, such as the HPV
DNA test, could enhance the efficacy of population-based
screening programs, either as a sole screening tool or as an
adjunct to current cervical cytologic screening. 
Recently, the detection of HPV infection depends almost
entirely on molecular methodologies, of which the Hybrid
Capture (HC) 2 assay (Qiagen, Gaithersburg, MD, U.S.A.)
is the only commercial HPV DNA test approved by the U.S.
Food and Drug Administration (FDA) (7, 8). The HC 2 assay
has also been approved in the U.S. as an adjunct to the Papani-
colaou test for cervical cancer screening for women aged over
30. While the HC 2 assay can detect 13 HR HPV genotypes,
it neither allows the identification of specific genotypes nor
provides any information about multiple HPV infections. 
Recent studies have provided evidence for a difference in
oncogenic potential among the HR HPV genotypes, high-
lighting the importance of HPV genotyping, particularly
HPV 16 and HPV 18 (9). There are numerous polymerase
chain reaction (PCR)-based HPV genotyping methods in
widespread use. The commercially available PCR-based HPV
genotyping methods have included the primer sets, GP5+/
GP6+ (10, 11) and MY09/11, and their subsequently modi-
fied derivatives PGMY09/11 (12, 13) and the SPF10 system
(14-16).
Recently, a novel PCR-based HPV detection and genotyp-
ing method has been developed, the HPV 4 Auto-capillary
eElectrophoresis (ACE) test (Seegene Inc., Seoul, Korea). In
contrast to other commercially available PCR methods, the
HPV 4 ACE test uses a newly-developed dual priming oli-
gonucleotide (DPO) system in order to minimize the risk of
non-specific priming. This test has the ability to identify HPV
16 and 18 genotypes and can detect 11 other HR HPVs. 
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Comparison of the Novel Human Papillomavirus 4 Auto-capillary 
Electrophoresis Test with the Hybrid Capture 2 Assay and with the
PCR HPV Typing Set Test in the Detection of High-Risk HPV 
Including HPV 16 and 18 Genotypes in Cervical Specimens 
The aim of this study was to compare the novel human papillomavirus (HPV) detec-
tion method, the HPV 4 Auto-capillary Electrophoresis (ACE) test with the hybrid
capture (HC) 2 assay for the detection of high-risk HPVs. In addition, we compared
the HPV 4 ACE test with the polymerase chain reaction HPV Typing Set test for the
detection of HPV 16 and HPV 18 genotypes. One hundred ninety-nine cervical swab
samples obtained from women with previous abnormal Pap smears were subject-
ed to testing with the three HPV tests. The HPV 4 ACE test and the HC 2 assay
showed substantial agreement for detection of high-risk HPVs (85.4%, kappa=0.71).
The HPV 4 ACE test also showed substantial agreement with the PCR HPV Typ-
ing Set test in the detection of HPV 16 and HP V 18 genotypes (89.9%, kappa=0.65).
In correlation with cytologic results, the sensitivities and specificities of the HPV 4
ACE test and HC 2 assay were 92.9% vs. 92.9% and 48.1% vs. 50.8%, respective-
ly, when high-grade squamous intraepithelial lesions were regarded as abnormal
cytologies. The novel HPV 4 ACE test is a valuable tool for the detection of high-risk
HPVs and for genotyping of HPV 16 and HPV 18. 
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Accepted : 14 March 2009In contrast, the PCR HPV Typing Set test (Takara Bio.,
Shiga, Japan), which is commercially available, uses two pri-
mer sets which can detect 7 HR (HPV-16, 18, 31, 33, 35, 52,
and 58) and 2 LR HPV genotypes (HPV-6 and 11) (17-20).
The purpose of this study was to evaluate the efficacy of the
HPV 4 ACE test, as compared to the HC 2 assay and the PCR
HPV Typing Set test for the detection of HR HPV DNA in
cervical swab samples. In addition, we compared the HPV
4 ACE test with the PCR HPV Typing Set test for the detec-
tion of HPV 16 and HPV 18. Finally, we evaluated the sen-
sitivity and specificity of these HPV DNA tests in correla-
tion with cytologic results.
MATERIALS AND METHODS
Study population and specimen collection
One hundred ninety-nine women who were referred to the
Colposcopy Clinic in Guro Hospital of Korea University for
abnormal cytology between April and June 2008 were pro-
spectively enrolled. A cervical specimen for liquid-based cytol-
ogy, along with simultaneous HPV DNA detection by the
HC 2 assay, was collected from each woman. Genomic DNA
was extracted from each sample and the HPV DNA tests
were performed by both the HPV 4 ACE test and the PCR
HPV Typing Set test on the same specimen. The study pro-
tocol was approved by the Institutional Review Board for
Research on Human Subjects at the Korea University Guro
Hospital, and written informed consent was obtained from
the patients. 
Liquid-based cytology
A Cervex-Brush (Rovers Medical Devices, Oss, The Nether-
lands) was used to obtain samples from the uterine cervix. The
brush was immediately rinsed in a vial of PreservCyt solu-
tion (Cytyc, Boxborough, MA, U.S.A.). The vial was placed
in the Thin Prep Processor (Cytyc). The ThinPrep slide was
then fixed in ethanol and stained with Papanicolaou’s stain.
The number of epithelial cells on these slides was estimated
from the number of cells contained within computer-derived
coordinates for 50 random fields located within a 20-mm
diameter circular area where the cells were deposited. The
diagnoses were made using the 2001 Bethesda System for
cervical cytology.
HC 2 assay
HPV DNA testing by the HC 2 assay was performed with
the HC 2 assay system according to the manufacturer’s pro-
tocol (Qiagen). The specimens were denatured at 65℃ for
45 min and hybridized under high-stringency conditions with
a mixture of RNA probes that detects 13 different oncogenic
HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
and 68. The resultant DNA-RNA hybrids were captured on
the surface of the microtiter plate wells coated with an anti-
DNA-RNA hybrid antibody. The immobilized hybrids were
then reacted with an alkaline phosphatase-conjugated anti-
hybrid monoclonal antibody. Light intensity was measured
with a luminometer. The recommended positivity threshold
of 1 pg/mL was used as a cutoff, and all specimens with a rel-
ative light unit/control (RLU/CO) ratio of ≥1.0 were con-
sidered positive.
HPV 4 ACE test
The residual cell in the PreservCyt solution were centrifug-
ed at 13,000×g for 15 min, and the cell pellets were resus-
pended in 200 μ L of phosphate-buffered saline. The resus-
pended cell pellets were added to a DNA purification col-
umn (Qiagen, Inc., Valencia, CA, U.S.A.). The extraction of
total DNA was performed according to the manufacturer’s
instructions. 
Briefly, PCR was conducted in a final reaction volume of
20 μ L containing 3 μ L of isolated DNA from cervical swab,
4 μ L of 5×HPV 4 ACE primer mixture, and 10 μ L of 2×
Master Mix (Seegene Inc.). The cycling conditions were as
follows: denaturation for 15 min at 94℃; amplification for
40 cycles, with denaturation for 30 sec at 94℃; annealing
for 1 min 30 sec at 60℃; and extension for 1 min 30 sec at
72℃. The amplified PCR products were separated in 2%
agarose gel stained with ethidium bromide or ScreeningTape
�
System (Lab901 Ltd., Edingurgh, U.K.). Briefly, following
PCR, 2 μ L of the amplification product was mixed with 6 μ L
loading buffer (Lab901) in a 0.2 mL PCR Tube. Insert the
sample block into the TapeStation (Lab901) and place the 0.2
mL PCR tube containing the sample. Amplicon analysis was
then performed on the ScreenTape System with the Seegene
View software. Seegene’s capillary electrophoresis system pro-
vide the detection software which automatically read the PCR
product and analyze the amplicon intensity while convention-
al capillary electrophoresis need user’s manual read of the peak
with naked eyes after mixing the PCR product with SYBR
green or Cyto-9 dye.
PCR HPV Typing Set test 
The DNA of swab was extracted from swabs using a QI-
Aamp DNA Micro Kit (Qiagen, Inc.) according to the man-
ufacturer’s instructions. The concentration of DNA was mea-
sured using a spectrophotometer (DU
�530; Beckman, Fuller-
ton, CA, U.S.A.), and the DNA quality was confirmed on
agarose gels. The PCR method using the HPV Typing Set
was used. The HPV subtype was determined using the HPV
Typing Set (Takara Bio., Shiga, Japan), a primer set for PCR
specifically designed to identify HPV genotypes 6, 11, 16,
18, 31, 33, 35, 52, and 58 in genomic DNA. The primer
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11 (LR HPV genotypes) and HPVpU-1M was used to ampli-
fy the DNA of HPV 16, 18, 31, 33, 35, 52, and 58 (HR HPV
genotypes). The PCR HPV Typing Set method was used
according to the manufacturer’s instructions. This set includes
both malignant and benign control templates for verification
of the PCR reaction by using the primer pairs provided in
the set. Their expression was normalized using the supplied
control template as an endogenous reference. Restriction en-
zyme digestion of PCR products can also be confirmed because
PCR products recognized the sites of Ava II, Afa I, Bgl II, Acc
I, and Ava I and small sizes of DNA fragments are yielded by
digestion of restriction enzymes. The DNA fragments were
confirmed on agarose gels and identified the HPV genotypes.
Statistical analysis
To compare the clinical accuracy of the HC 2 assay, the HPV
4 ACE test, and the PCR HPV typing set test to detect high-
grade cervical lesions, we also calculated the sensitivity, speci-
ficity, positive predictive value (PPV), and negative predic-
tive value (NPV); the sensitivity and specificity of the three
tests were compared by the paired proportion test.
Agreement between the HPV assays was assessed by Cohen’s
kappa statistic, with values of 0.00-0.20 indicating poor agree-
ment, 0.21-0.40 fair agreement, 0.41-0.60 moderate agree-
ment, 0.61-0.80 substantial agreement, and 0.81-1.00 almost
perfect agreement. McNemar’s chi-square analysis for matched
pair data was performed to analyze contingency tables com-
paring HPV tests. Statistical analyses were performed with
SPSS, version 12.0, statistical software (Chicago, IL, U.S.A.).
All tests were two-sided, and a P value <0.05 was considered
significant.
RESULTS
The cytologic findings, as well as all three HPV DNA test
results, were available for 199 patients. The overall HR HPV
detection rates were 52.3% (104/199) by the HC 2 assay,
54.3% (108/199) by the HPV 4 ACE test, and 48.7% (97/
199) by the PCR HPV Typing Set test (Table 1). The HR
HPV-positive rates by the HC 2 assay, HPV 4 ACE test, and
PCR HPV Typing Set test were 31.4%, 37.3%, and 33.3%,
for the normal cytology group, 65.5%, 61.8%, and 58.2%
for atypical squamous cells of undetermined significance (AS-
CUS), 82.1%, 82.1%, and 60.7% for low-grade squamous
intraepithelial lesion (LSIL), respectively. In the cytologic high-
grade squamous intraepithelial lesion (HSIL) group, which
is clinically important for its tendency to progress to cervi-
cal cancer, all 3 tests showed identical positivity rates (87.5%),
and a 100% HR HPV detection rate was observed in the cer-
vical cancer group by all 3 tests. The HPV 4 ACE test did
not show any significant difference in HR HPV positivity
in the normal cytology group from the HC 2 assay and the
PCR HPV Typing Set test (P=0.143 and P=0.585, respec-
tively). However, there were 17 discordant samples between
the HC 2 assay and the HPV 4 ACE test in normal Pap smear
samples; 5 samples were HC 2-positive and HPV 4 ACE-
negative, and 12 samples were HC 2-negative and HPV 4
ACE-positive. Of 12 samples, 4 included HR HPV geno-
types (HPV 16/18, 16/33/58, 16/31, and 52), which were
identified by the PCR HPV Typing Set test. In contrast, there
were no HR genotypes identified in the former 5 samples.
In cytologic ASCUS, the detection rate of the HPV 4 ACE
test for HR HPV was also not significantly different from
the HC 2 assay and the PCR HPV Typing Set test, but the
HC 2 assay showed a significantly higher detection rate for
HR HPV than PCR HPV Typing Set test (P=0.02). With
the HC 2 assay and the HPV 4 ACE test, a significantly higher
percentage of LSIL Pap smear samples tested positive for HR
HPV than with the PCR HPV Typing Set test (82.1% vs.
60.7%, P=0.03). In women with cytologic HSIL, the HPV
4 ACE test showed a detection rate of 87.5% for HR HPV,
which was the same level as that of both the HC 2 assay and
the PCR HPV Typing Set test. 
The concordance for HR HPV detection between the HC
2 assay and the HPV 4 ACE test was 85.4%, showing sub-
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HPV, human papillomavirus; HC, hybrid capture; ACE, auto-capillary
electrophoresis; PCR, polymerase chain reaction; WNL, within normal
limit; ASC-US, atypical squamous cells-undetermined significance; LSIL,




No. (%) positive samples




WNL 32 (31.4) 38 (37.3) 34 (33.3) 102 (51.3)
ASC-US 36 (65.5) 34 (61.8) 32 (58.2) 55 (27.6)
LSIL 23 (82.1) 23 (82.1) 17 (60.7) 28 (14.1)
HSIL 7 (87.5) 7 (87.5) 7 (87.5) 8 (4.0)
Cervical cancer 6 (100.0) 6 (100.0) 6 (100.0) 6 (3.0)
Total 104 (52.3) 108 (54.3) 97 (48.7) 199 (100.0)
Table 1. HPV DNA test results according to cytological diagnosis
*Concordance for the detection of high-risk HPVs; 
� concordance for
the detection of HPV 16 and HPV 18 genotypes.
HC, hybrid capture; HPV, human papillomavirus; ACE, auto-capillary











HC 2-HPV 4 ACE* 92 78 85.4% 0.71
HC2-PCR Typing* 73 71 72.4% 0.45
HPV 4 ACE-PCR  25 154 89.9% 0.65
Typing
�
Table 2. Concordance among HC 2 assay, HPV 4 ACE test and
PCR HPV typing set teststantial agreement (kappa coefficient=0.71; Table 2). In con-
trast, the concordance between the HC 2 assay and the PCR
HPV Typing Set test was 72.4%, showing moderate agree-
ment (kappa coefficient=0.45). For the detection of HPV 16
and HPV 18, the HPV 4 ACE test and the PCR HPV Typ-
ing Set test showed substantial agreement (89.9%, kappa
coefficient=0.65). However, 20 cases (10.1%) gave discor-
dant results; specifically, 8 cases were positive by the HPV 4
ACE test, but negative by the PCR HPV Typing Set test,
whereas 12 samples were PCR HPV Typing Set test-positive,
but HPV 4 ACE-negative (Table 3).
Table 4 shows the HR HPV detection related to cytologic
results. The overall HR HPV prevalence increased in parallel
with the increasing severity of the Pap smear result. When
an abnormal Pap test was defined as ASCUS or higher, the
sensitivity and specificity of the HPV 4 ACE test were not
inferior to the HC 2 assay (72.2% vs. 74.2% [P=0.40], and
61.8% vs. 68.6% [P=0.27], respectively; Table 4). In addi-
tion, the sensitivity and the specificity of the HPV 4 ACE test
were also comparable to the PCR HPV Typing Set test (P=
0.27 and 0.36, respectively). 
When the abnormal Pap test was defined as LSIL or higher,
all three HPV DNA tests performed similarly for the detec-
tion of HR HPV DNA (data not shown). Furthermore, with
respect to cytologic HSIL or cervical cancer, all 3 tests had
the same level of sensitivity (92.9%) and a similar level of
specificity (Table 4). 
DISCUSSION
The purpose of this study was to examine the performance
of the novel HPV 4 ACE test for the detection of HR HPV
and HPV 16 and 18 genotypes, as compared to the HC 2
assay and the PCR HPV Typing Set test. Since the approval
by the U.S. FDA, the HC 2 assay has been used as a gold stan-
dard when evaluating the efficacy of the various novel HPV
DNA detection methods (21-24). In addition, the PCR HPV
Typing Set test has been widely used for the detection of HPV
in a number of studies (17-20). 
Given that the HPV 4 ACE test has only recently become
commercially available, there is no study to compare this test
with other HPV detection methods. The HPV 4 ACE test
can identify HPV 16 and HPV 18 genotypes among 13 high-
risk HPVs and can detect the presence of other 11 high-risk
HPVs. For this aspect, the novel HPV 4 ACE test can be called
as an upgraded version of the HC 2 assay. Because of the over-
whelming importance of the HPV 16 and 18 genotypes in
the progression to high-grade cervical lesions, genotyping of
the HPV 16 and 18 with simultaneous detection of 11 other
high-risk HPVs seem to be very efficacious, as compared to
other PCR-based genotyping methods or HPV DNA chip.
The HPV 4 ACE test uses a dual priming oligonucleotide
(DPO) system that is structurally and functionally different
from the primer system currently in widespread use. The con-
ventional priming system is based on a single priming event
between the primer and template, which often leads to exten-
sion of non-specific products. In contrast, the DPO system
has two separate primer segments (a 5′ -segment 18-25nt in
length and a 3′ -segment 6-12nt in length). This unequal dis-
tribution of nucleotides leads to different annealing prefer-
ences for each segment. The longer 5′ -segment preferential-
ly binds to the template DNA and initiates stable annealing,
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2 Positive Positive* 18, 52, 58 ASC-US
4 Negative Negative 18, 52, 58 ASC-US
16 Negative Positive 16, 18 Normal
25 Negative Positive 16, 33, 58 Normal
33 Positive Positive 16, 52 LSIL
40 Negative Negative 16,18 Normal
47 Negative HPV-16 0 ASC-US
50 Negative HPV-16 0 ASC-US
51 Positive Positive 16 ASC-US
76 Positive HPV-16 42, 43, 44 ASC-US
87 Positive Positive 16 LSIL
116 Positive HPV-16 31, 52 Normal
120 Positive Positive 16,18 Normal
125 Positive Positive 16, 18, 31, 58 HSIL
161 Positive HPV-16 31 Normal
162 Positive Positive 18 ASC-US
168 Positive HPV-16 31,52 Normal
170 Positive HPV-16 58 ASC-US
186 Positive Positive 16 ASC-US
197 Positive HPV-16 52 Normal
Table 3. Overview of discordant samples between HPV 4 ACE
test and PCR HPV Typing Set test 
*positive, positive for 11 high-risk HPVs other than HPV 16 and 18 geno-
types.
HPV, human papillomavirus; ACE, auto-capillary electrophoresis; PCR,
polymerase chain reaction; HC, hybrid capture; ASC-US, atypical squa-
mous cells-undetermined significance; LSIL, low grade squamous intraep-
ithelial lesions; HSIL, high grade squamous intraepithelial lesions.
HPV, human papillomavirus; ACE, auto-capillary electrophoresis; PCR,
polymerase chain reaction; HC, hybrid capture; ASC-US, atypical squa-
mous cells-undetermined significance; HSIL, high grade squamous in-

















Sensitivity 74.2% 72.2% 63.9% 92.9% 92.9% 92.9%
Specificity 68.6% 61.8% 65.7% 50.8% 48.1% 54.6%
PPV 69.2% 64.2% 63.9% 12.5% 11.9% 13.4%
NPV 73.7% 70.0% 65.7% 98.9% 98.9% 99.0%
Table 4. Overview of diagnostic accuracy of each HPV DNA testswhereas the short 3′ -segment selectively binds to its target
site and blocks non-specific annealing (25). 
In the present study, the HPV 4 ACE test showed the same
or comparable levels of the HR HPV detection rate, as com-
pared to the HC 2 assay and the PCR HPV Typing Set test.
In addition, the HPV 4 ACE test revealed substantial agree-
ment with the HC 2 assay for the detection of 13 HR HPVs.
In contrast, the PCR HPV Typing Set test showed a lower
concordance level than the HPV 4 ACE test with the HC 2
assay, which might be partially attributed to the differences
in the number of HR HPVs that could be detected by both
tests. The PCR HPV Typing Set test can only detect 7 HR
HPVs, whereas 13 types can be detected by the HC 2 assay.
Furthermore, in terms of HPV genotyping, particularly the
HPV 16 and HPV 18 genotypes, the HPV 4 ACE test also
showed substantial agreement with the PCR HPV Typing
Set test. As shown in Table 3, 20 samples were discordant
between the HPV 4 ACE test and the PCR HPV Typing Set
test. Although the HPV 4 ACE test failed to detect HPV 16
or HPV 18 in 12 of 20 samples, there were only 2 samples
negative for any HR HPV. Furthermore, these two cases were
shown to be 1 normal and 1 ASCUS in cytology, not squa-
mous intraepithelial lesions. 
A recent study reported by Sandri et al. (21) compared the
AMPLICOR HPV test with the HC 2 assay for the detec-
tion of 13 HR HPVs. The AMPLCOR HPV test is similar
to the HPV 4 ACE test in terms of PCR-based HPV detec-
tion methods. In their study, the HR HPV DNA detection
rate of the AMPLICOR HPV test was higher than the HC
2 assay in normal Pap smear samples, whereas the two tests
performed similarly on abnormal Pap smear results. In con-
trast, our study showed no significant difference between the
two tests for HR HPV DNA positivity, regardless of cyto-
logic results. 
Another study performed by Stevens et al. (22) evaluated
the performance of the HC 2 assay and the AMPLICOR HPV
test according to cytologic results. In cytologic HSIL or high-
er, the sensitivity of the HC 2 assay and the AMPLICOR HPV
test were 87.4% and 95.2%, respectively, which was similar
to our results. When compared to another PCR-based HPV
DNA detection method already in use, such as the AMPL-
ICOR test, the novel HPV 4 ACE test showed comparable
sensitivity for the detection of HR HPV. 
With respect to the PCR HPV Typing Set test, Fujinaga
et al. (18) evaluated the performance of this test in 39 cervi-
cal carcinoma tissue specimens. According to their report, the
overall prevalence of HR HPV was 84.6%, of which there
were 19 HPV 16-positive specimens and 5 HPV 18-positive
specimens. In our study, although evaluated in cytology sam-
ples, the HR HPV detection rate was 100% in 6 cervical
cancers. Among 6 samples, 4 HPV 16-positive and 1 HPV
18-positive samples were identified.
Our study had some limitations. First, the number of sam-
ples with cytologic LSIL or higher were not sufficient to con-
clude our results. Second, we could not evaluate the perfor-
mance of HPV DNA tests using tissue samples due to loss of
follow-up. For that reason, we evaluated the sensitivity and
specificity of the three HPV tests using cytology specimens in
three different conditions, that is the ‘‘disease’’ was defined as;
1) ASC-US or worse, 2) LSIL or worse, and 3) HSIL or worse.
Nevertheless, our study showed that the novel HPV 4 ACE
test can substitute for the various HPV DNA tests already
in use, particularly the HC 2 assay. The HPV 4 ACE test is
basically the same test as HC2 assay in terms of detecting 13
high-risk HPVs. But the difference between the two tests is
that HPV 4 ACE test can give the information about the pres-
ence of HPV 16 and 18 genotypes, which account for about
70% of cervical cancer. So we can not only detect other 11
high-risk HPVs but also genotype the HPV 16 and 18 simul-
taneously by performing the HPV 4 ACE test. This is very
important difference in that knowledge about the presence of
HPV 16 and 18 would be helpful to triage the patients who
are needed to get frequent follow-up or not. Furthermore, in
the era of HPV vaccination, information regarding specific
carcinogenic HPV genotypes identified by HPV DNA tests,
such as the HC 2 assay in women positive for HR HPV, would
be helpful for discriminating women with clinically-relevant
diseases that are most likely to progress from those with dis-
eases that regress spontaneously. In addition, persistent infec-
tion with HR HPV genotypes, such as HPV 16 and HPV
18, is known to be a necessary condition for the development
of high-grade cervical intraepithelial neoplasia and invasive
disease (26). Therefore, selective HPV genotyping for HR
HPV genotypes would be crucial for distinguishing women
who are at high risk for progression from those who are likely
to regress. 
Thus, the HPV 4 ACE test has the ability to detect the
presence of 13 HR HPVs and also to identify HPV 16 and
HPV 18 genotypes simultaneously in high concordance with
the HC 2 assay. To make this novel diagnostic tool more cred-
ible, further studies with larger samples and comparison with
other various HPV DNA genotyping methods is needed.
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